Arcellx to present positive data on multiple myeloma treatments

Phase 1 and 2 studies show promising results for anito-cel therapy

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on anitocabtagene autoleucel (anito-cel) for treating relapsed or refractory multiple myeloma.

These findings will be showcased at the 66th American Society of Haematology (ASH) Annual Meeting in San Diego from December 7-10.

In the phase 1 study, anito-cel achieved a median progression-free survival (PFS) of 30.2 months with a 38.1-month follow-up. Dr Rami Komrokji, the principal investigator, remarked, “The results signify a substantial advancement in treatment options for multiple myeloma patients.”

Preliminary data from the iMMagine-1 phase 2 study demonstrated a 95% overall response rate (ORR) and 62% complete response/stringent complete response (CR/sCR) in 58 patients.

Median follow-up was 10.3 months. “These findings are encouraging and highlight the potential of anito-cel in providing durable responses,” said Dr Anita Kumar, another leading researcher.

Importantly, no delayed neurotoxicities, such as parkinsonism or cranial nerve palsies, were observed.

This marks an improvement in the safety profile, with 79% of patients experiencing no severe cytokine release syndrome (CRS).

Arcellx also announced the dosing of the first patient in its iMMagine-3 study, manufactured by Kite. The company will host a live webcast with clinical experts on December 9 to discuss the findings in detail.

“The absence of neurotoxicities and high response rates in the iMMagine-1 study are particularly noteworthy,” added Kumar.

As Arcellx continues its research, the biotech community is keen to see how these promising results could change the landscape of multiple myeloma treatment.